Skip to main content
SpringerLink
Log in

HMG-CoA Reductase Inhibitor Use in the Aged

A Review of Clinical Experience

  • Review Articles
  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

While the benefit of cholesterol-lowering in the elderly has yet to be proven in clinical trials, individuals at high risk of coronary events who otherwise enjoy a good quality of life, should not be denied cholesterol-lowering therapy on the basis of age alone. Moreover, hypolipidaemic drugs are already extensively used in the aged. The HMG-CoA reductase inhibitors lovastatin, simvastatin and pravastatin are potent well tolerated hypolipidaemic therapies in young subjects. Although there have been few studies on their use in elderly subjects, the available data suggest the efficacy and safety of HMG-CoA reductase inhibitors is similar to that established for younger age groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Agner E, Hansen PF. Fasting serum cholesterol and triglycerides in a 10-year prospective study in old age. Acta Medica Scan-dinavica 214: 33–41, 1983

    Article  CAS  Google Scholar 

  • Ahmad S. Lovastatin warfarin interaction. Correspondence. Archives of Internal Medicine 150: 2407, 1990

    Article  PubMed  CAS  Google Scholar 

  • Anderson GM, Newhouse JP, Roos LL. Hospital care for elderly patients with diseases of the circulatory system. A comparison of hospital use in the United States and Canada. New England Journal of Medicine 321: 1443–1448, 1989

    Article  PubMed  CAS  Google Scholar 

  • Aviram M, Cogan U, Dankner G, Hochgraf E, Brook GJ. LDL oxidation is inhibited by lovastatin. Abstract. Arteriosclerosis 10: 793a, 1990

    Google Scholar 

  • Bach LA, Cooper ME, O’Brian RC, Jerums G. The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis. Journal of the American Geriatrics Society 38: 10–14, 1990

    PubMed  CAS  Google Scholar 

  • Barth JD, Kruisbrink OAE, Van Dijk AL. Inhibitors of hydroxy-methylglutaryl coenzyme A reductase for treating hyperchol-esterolaemia. Correspondence. British Medical Journal 301: 669, 1990

    Article  PubMed  CAS  Google Scholar 

  • Bates MC, Warren SG, Grubb S, Chillag S. Effectiveness of low-dose lovastatin in lowering serum cholesterol. Archives of Internal Medicine 150: 1947–1950, 1990

    Article  PubMed  CAS  Google Scholar 

  • Beigel Y, Fuchs J, Snir M, Lurie Y, Green P, et al. Lovastatin therapy in heterozygous familial hypercholesterolaemic patients: effect on blood rheology and fibrinogen levels. Journal of Internal Medicine 230: 23–27, 1991

    Article  PubMed  CAS  Google Scholar 

  • Benfante R, Reed D. Is elevated serum cholesterol a risk factor for coronary heart disease in the elderly? Journal of the American Medical Association 263: 393–396, 1990

    Article  PubMed  CAS  Google Scholar 

  • Berg K, Leren TP. Unchanged serum lipoprotein (a) concentrations with lovastatin. Correspondence. Lancet 2: 812, 1989

    Article  PubMed  CAS  Google Scholar 

  • Bilheimer DW. Clinical considerations regarding treatment of hypercholesterolaemia in the elderly. Atherosclerosis 91: S35–S57, 1991

    Article  PubMed  Google Scholar 

  • Bilheimer DW. Long-term clinical tolerance of lovastatin and simvastatin. Cardiology 77(4): 58–65, 1990

    Article  PubMed  Google Scholar 

  • Black DM, Lucas MM, Versoza S, Stein EA. Effectiveness and safety of lovastatin and simvastatin in men and women over age 70. Arteriosclerosis Dallas 10(5): 848a, 1990

    Google Scholar 

  • Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. Journal of the American Medical Association 257: 3233–3240, 1987

    Article  PubMed  CAS  Google Scholar 

  • Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. Archives of Internal Medicine 151: 43–49, 1991

    Article  PubMed  CAS  Google Scholar 

  • Crepaldi G, Baggio G, Arca M, Avellone P, Bittolo G, et al. Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolaemia. Archives of Internal Medicine 151: 146–152, 1990

    Article  Google Scholar 

  • D’Agostino RB, Kannel WB, Stepanians MN, D’Agostino LC. A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolaemia. American Journal of Cardiology 69: 28–34, 1992

    Article  PubMed  Google Scholar 

  • Denke MA, Grundy SM. Hypercholesterolaemia in elderly persons: resolving the treatment dilemma. Annals of Internal Medicine 112: 780–792, 1990

    PubMed  CAS  Google Scholar 

  • Ditschuneit HH, Kuhn K, Ditschuneit H. Comparison of different HMG-CoA reductase inhibitors. Clinical Pharmacology 40(Suppl. 1): S27–S32, 1991

    Google Scholar 

  • East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidaemia. Annals of Internal Medicine 109: 25–32, 1988

    PubMed  CAS  Google Scholar 

  • Emmerich J, Aubert I, Bauduceau B, Dachet C, Chanau B, et al. Efficacy and safety of simvastatin (alone or in association with cholestyramine). A 1-year study in 66 patients with type II hyperlipoproteinaemia. European Heart Journal 11: 149–155, 1990

    PubMed  CAS  Google Scholar 

  • Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. Journal of Antibiotics 29: 1346–1348, 1976

    Article  PubMed  CAS  Google Scholar 

  • Erkelens DW. Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia. Cardiology 77(Suppl. 4): 33–38, 1990

    Article  PubMed  Google Scholar 

  • Erkelens DW, Baggen MGA, Van Doormaal JJ, Kettner M, Koningsberger JC, et al. Clinical experience with simvastatin compared with cholestyramine. Drugs 36(Suppl. 3): 87–92, 1988

    Article  PubMed  Google Scholar 

  • Franceschini G, Sirtori M, Vaccarino V, Gianfranceschii G, Chiesa G, et al. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia. Journal of Laboratory and Clinical Medicine 114: 250–259, 1989

    PubMed  CAS  Google Scholar 

  • French JK, White HD, Greaves SC. Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease. New Zealand Medical Journal 103: 41–43, 1990

    PubMed  CAS  Google Scholar 

  • Fries JF, Green LW, Levine S. Health promotion and the compression of morbidity. Lancet 1: 481–483, 1989

    Article  PubMed  CAS  Google Scholar 

  • Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. New England Journal of Medicine 318: 81–86, 1988

    Article  PubMed  CAS  Google Scholar 

  • Germershausen JI, Hunt VM, Bostedor RG, Bailey PJ, Karkas JD, et al. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochemical and Biophysical Research Communications 158: 667–675, 1989

    Article  PubMed  CAS  Google Scholar 

  • Giannini SD, De Goes JM, Dereviack BE, Machao C, Forti N, et al. Simvastatin (MK-733), A new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis. (Portuguese with English summary, not translated.) Arq. Bras. Cardiology 54: 406–414, 1990

    Google Scholar 

  • Gluek CJ, Speirs J, Tracy T. Safety and efficacy of combined gemfibrozil-lovastatin therapy for primary dyslipoproteinemias. Journal of Laboratory and Clinical Medicine 115: 603–9, 1990

    Google Scholar 

  • Goldstein MR. Myopathy and rhabdomyolysis with lovastatin taken with gemfibrozil. Correspondence. Journal of the American Medical Association 264: 2991, 1990

    Article  Google Scholar 

  • Harris T, Cook EF, Kannel WB, Golman L. Proportional hazards analysis of risk factors for coronary heart disease in individual aged 65 or older. The Framingham Heart Study. Journal of the American Geriatrics Society 36: 1023–1028, 1988

    PubMed  CAS  Google Scholar 

  • Havel RJ, Hunninghake DB, Illingworth DR, Lees RS, Stein EA, et al. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolaemia. Annals of Internal Medicine 107: 609–615, 1987

    PubMed  CAS  Google Scholar 

  • Hayden MR, Frolich JJ, Kastelein JJ, Gregoire S, Rabkin S. Therapeutic response to simvastatin in elderly patients with primary hypercholesterolemia. Abstract. 8th International Symposium on Atherosclerosis p.355, 1988

    Google Scholar 

  • Helve E, Tikkanen MJ. Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolaemia: different effects on lipoprotein profiles. Atherosclerosis 72: 189–197, 1988

    Article  PubMed  CAS  Google Scholar 

  • Hoogerbrugge N, Mol MJTM, Van Dormaal JJ, Rustemeijer C, Mulss E, et al. The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia. Journal of Internal Medicine 228: 261–266, 1990

    Article  PubMed  CAS  Google Scholar 

  • Hunninghake DB, Knopp RH, Schonfeld G, Goldberg AC, Brown VW, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolaemia. Atherosclerosis 85: 81–89, 1990

    Article  PubMed  CAS  Google Scholar 

  • Illingworth DR, Bacon S. Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia. Circulation 79: 590–596, 1989

    Article  PubMed  CAS  Google Scholar 

  • Illingworth Dr, Bacon SP, Larsen KK. Long term experience with HMG CoA reductase inhibitors in the therapy of hypercholesterolaemia. Atherosclerosis Reviews 18: 161–187, 1988

    Google Scholar 

  • Ito H. The effects of CS-514 (pravastatin), an inhibitor of 3-hy-droxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipids and steroid hormones in the hypercholesterolemic elderly. Journal of Clinical Therapeutics and Medicines 4: 395–407, 1988

    Google Scholar 

  • Jacob BG, Richter WO, Schwandt P. Lovastatin, pravastatin, and serum lipoprotein (a). Annals of Internal Medicine 112: 713–714, 1990

    PubMed  CAS  Google Scholar 

  • Jay RH, Rampling MW, Betteridge DJ. Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment. Atherosclerosis 85: 249–256, 1990

    Article  PubMed  CAS  Google Scholar 

  • Jerums G, Bach L, Cooper M, O’Brian R. A double-blind randomised trial of HMGCOA reductase inhibition with MK-733 in elderly patients with hypercholesterolaemia. Abstract. 8th International Symposium on Atherosclerosis: 424, 1988

  • Jurgens G, Ashy A, Zenker G. Raised serum lipoprotein during treatment with lovastatin [Letter]. Lancet 1: 911–912, 1989

    Article  PubMed  CAS  Google Scholar 

  • Kannel WB, D’Aostino RB, Stepanians M, D’Agostino LC. Efficacy and tolerability of lovastatin in a six-month study: analysis by gender, age and hypertensive status. American Journal of Cardiology 66: 1B–10B, 1990

    Article  PubMed  CAS  Google Scholar 

  • Kashyap ML. Cardiovascular disease in the elderly: current considerations. American Journal of Cardiology 63: 3H–4H, 1989

    Article  PubMed  CAS  Google Scholar 

  • Koppensteiner R, Minar E, Ehringer H. Effect of lovastatin on hemorheology in type II hyperlipoproteinemia. Atherosclerosis 83: 53–58, 1990

    Article  PubMed  CAS  Google Scholar 

  • Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, et al. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 80: 1313–1319, 1989

    Article  PubMed  CAS  Google Scholar 

  • Kuhn P, Darioli R, Bovet P, Bercher L, Brunner HR. Dose-dependent lipid-lowering effects of simvastatin (MK-733) in the elderly. Current Therapeutic Research 46: 381–389, 1989

    Google Scholar 

  • Leren TP, Hjermann I, Berg K, Leren P, Foss OP, Viksmoen L. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis 73: 135–141, 1988

    Article  PubMed  CAS  Google Scholar 

  • Lintott CJ, Scott RS, Nye ER, Robertson MC, Sutherland WHF. The hypolipidaemic effects of pravastatin (CS-514) alone and in combination with bezafibrate or acipimox in patients with primary hypercholesterolaemia. Diabetes, Nutrition & Metabolism 4: 117–122, 1991b

    Google Scholar 

  • Lintott CJ, Scott RS, Nye ER, Robertson MC, Sutherland WHF. Simvastatin (MK 733): an effective treatment for hypercholesterolaemia. Australia and New Zealand Journal of Medicine 19: 317–320, 1989

    Article  CAS  Google Scholar 

  • Lintott CJ, Scott RS, Sharpe DN, Nye ER, Charleson H, et al. Treatment of primary hypercholesterolaemia with simvastatin: New Zealand multicentre evaluation. Medical Journal of Australia 155: 433–436, 1991a

    PubMed  CAS  Google Scholar 

  • Lintott CJ, Scott RS, Sutherland WHF, Bremer JM, Shand BI, et al. Comparison of simvastatin vs gemfibrozil therapy on lipid, glycaemic, and haemorheological parameters in type II diabetes mellitus. Diabetes, Nutrition & Metabolism, in press, 1992

  • Malenka DJ, Baron JA. Cholesterol and coronary heart disease. The importance of patient-specific attributable risk. Archives of Internal Medicine 149: 2247–2252, 1988

    Article  Google Scholar 

  • Malini PL, Ambrosioni E, De Divitiis O, Di Somma S, Rosiello G, et al. Simvastatin versus pravastatin: efficacy and tolerability in patients with primary hypercholesterolaemia. Clinical Therapeutics 13: 500–510, 1991

    PubMed  CAS  Google Scholar 

  • Mauro VF, MacDonald JL. Simvastatin: a review of its pharmacology and clinical use. DICP: Annals of Pharmacotherapy 25: 257–264, 1991

    PubMed  CAS  Google Scholar 

  • McDowell IFW, Smye M, Trinick T, Shortt JA, Archibald MP, et al. Simvastatin in severe hypercholesterolaemia: a placebo controlled trial. British Journal of Clinical Pharmacology 31: 340–343, 1991

    Article  PubMed  CAS  Google Scholar 

  • McTavish D, Sorkin EM. Pravastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 42: 65–89, 1991

    Article  PubMed  CAS  Google Scholar 

  • Mino Y. Effects of pravastatin on hypercholesterolemia in the elderly. In Abstracts, 9th International Symposium on Atherosclerosis: 190, 1991

  • Morgan T, Anderson A, McDonald P, Hopper J, Macaskill G. Simvastatin in the treatment of hypercholesterolaemia in patients with essential hypertension. Journal of Hypertension 8(1): S25–S32, 1990

    Article  PubMed  CAS  Google Scholar 

  • Nakandakare E, Garcia RC, Rocha JC, Sperotto G, Oliveira HCF, et al. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins. Atherosclerosis 85: 211–217, 1990

    Article  PubMed  CAS  Google Scholar 

  • Nonis A, Brighenti G, Fratini M, Schwarz E. Controlled clinical trial on the treatment of hypercholesterolemia in elderly affected by cardiovascular disease. Diet versus Simvastatin. Arteriosclerosis Dallas 10(5): 809a, 1990

    Google Scholar 

  • Nozaki S, Vega GL, Haddox RJ, Dolan ET, Grundy SM. Influence of lovastatin on concentrations and composition of lipoprotein subfractions. Atherosclerosis 84: 101–110, 1990

    Article  PubMed  CAS  Google Scholar 

  • O’Brian RC, Simons LA, Clifton P, Cooper ME, Jennings GL, et al. Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolaemia. Medical Journal of Australia 152: 480–483, 1990

    Google Scholar 

  • Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, et al. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. Journal of Clinical Pharmacology 30: 1128–1135, 1990

    PubMed  CAS  Google Scholar 

  • Paolisso G, Sgambato S, De Riu S, Gambardella A, Verza M, et al. Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics. European Journal of Clinical Pharmacology 40: 27–31, 1991

    Article  PubMed  CAS  Google Scholar 

  • Pappu AS, Illingworth DR. Contrasting effects of lovastatin and cholestyramine on low-density-lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolaemia. Journal of Laboratory and Clinical Medicine 114: 554–562, 1989

    PubMed  CAS  Google Scholar 

  • Pierce R, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. Journal of the American Medical Association 264: 71–75, 1990

    Article  PubMed  CAS  Google Scholar 

  • Pietro DA, Alexander S, Mantell G, Staggers JE, Cook TJ. Effects of simvastatin and probucol in hypercholesterolaemia (Simvastatin Multicenter Study Group II). American Journal of Cardiology 63: 682–686, 1989

    Article  PubMed  CAS  Google Scholar 

  • Rubin SM, Sidney S, Black DM, Browner WS, Hulley SB, et al. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Annals of Internal Medicine 113: 916–919, 1990

    PubMed  CAS  Google Scholar 

  • Sahni R, Maniet AR, Voci G, Banka VS. Prevention of restenosis ny lovastatin after successful coronary angioplasty. American Heart Journal 121: 1600–1608, 1991

    Article  PubMed  CAS  Google Scholar 

  • Saito Y, Yoshida S, Nakaya N, Hata Y, Goto Y. Comparison of morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arteriosclerosis and Thrombosis 11: 816–826, 1991

    Article  PubMed  CAS  Google Scholar 

  • Sandset PM, Lund H, Norseth J, Abildgaard U, Ose L. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arteriosclerosis and Thrombosis 11: 138–145, 1991

    Article  PubMed  CAS  Google Scholar 

  • Saxenhofer H, Weidmann P, Reisen WF, Beretta-Piccoli C, Fragiacomo C, et al. Therapeutic efficacy of the HMG-CoA-re-ductase inhibitor pravastatin in hyperlipoproteinemia type II. European Journal of Clinical Pharmacology 39: 101–105, 1990

    Article  PubMed  CAS  Google Scholar 

  • Schaefer EJ. HMG-CoA reductase inhibitors for hypercholesterolemia. New England Journal of Medicine 319: 1222–1223, 1988

    Article  Google Scholar 

  • Scott RS, Lintott CJ, Wilson MJ. Simvastatin and side effects. New Zealand Medical Journal 104: 493–495, 1991

    PubMed  CAS  Google Scholar 

  • Simons LA. Epidemiologic considerations in cardiovascular diseases in the elderly: international comparisons and trends. American Journal of Cardiology 63: 5H–8H, 1989

    Article  PubMed  CAS  Google Scholar 

  • Stein E, Kreisberg R, Miller V, Mantell G, Washington L, Multicenter Group I. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Archives of Internal Medicine 150: 341–345, 1990

    Article  PubMed  CAS  Google Scholar 

  • The Lovastatin Study Group IV. A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. American Journal of Cardiology 66: 22B–30B, 1990

    Article  Google Scholar 

  • Tikkanen MJ, Tilvis RS. Hypercholesterolaemia in aged patients. To treat or not to treat? Drugs & Aging 1: 427–430, 1991

    Article  CAS  Google Scholar 

  • Todd PA, Goa KL. Simvastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 40: 583–607, 1990

    Article  PubMed  CAS  Google Scholar 

  • Walker JF. Simvastatin: the clinical profile. American Journal of Medicine 87(4A): 44S–46S, 1989

    Article  PubMed  CAS  Google Scholar 

  • Weisweiler P. Simvastatin and bezafibrate: effects of serum lipoproteins and lecithin: cholesterol acyltransferase activity in familial hypercholesterolaemia. European Journal of Clinical Pharmacology 35: 579–583, 1988

    Article  PubMed  CAS  Google Scholar 

  • Wiklund O, Angelin B, Fager G, Eriksson M, Olofsson S-O, et al. Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. Journal of Internal Medicine 228: 241–247, 1990

    Article  PubMed  CAS  Google Scholar 

  • Wysowski DK, Kennedy DL, Gross TP. Prescribed used of cholesterol-lowering drugs in the United States, 1978 through 1988. Journal of the American Medical Association 263: 2185–2188, 1990

    Article  PubMed  CAS  Google Scholar 

  • Yoshino G, Kazumi T, Iwai M, Matsushita M, Matsuba K, et al. Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514). Atherosclerosis 75: 67–72, 1989

    Article  PubMed  CAS  Google Scholar 

  • Yuan J, Tsai MY, Hegland J, Hunninghake DB. Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis 87: 147–157, 1991

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lipid and Diabetes Research Group, Hagley, Christchurch Hospital, 2nd Floor, Christchurch 1, New Zealand

    Caroline J. Lintott & Russell S. Scott

Authors
  1. Caroline J. Lintott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Russell S. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lintott, C.J., Scott, R.S. HMG-CoA Reductase Inhibitor Use in the Aged. Drug & Aging 2, 518–529 (1992). https://doi.org/10.2165/00002512-199202060-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199202060-00007

Keywords

Search

Navigation